Leveraging vaccine policy and investments for the AMR challenge

Philosophical Transactions of the Royal Society B Biological Sciences 2026 Open access

Read full text
Authors: Nidhee Jadeja, Mateusz Hasso-Agopsowicz, Marta Urrutxi Gallastegi, Maya Malarski, Michelle Jiménez, Birgitte K. Giersing, Marta Tufet
DOI: 10.1098/rstb.2025.0010
Cited by: 1
References: 15

Abstract

In this commentary, we reflect on GAVI's experience incorporating an antimicrobial resistance (AMR) criterion into the Vaccine Investment Strategy to explore how global vaccine policy can more integrate AMR objectives, and identify priority actions for maximizing the AMR impact of vaccines. This article is part of the Royal Society Science+ meeting issue 'Vaccines and antimicrobial resistance: from science to policy'.

Fields of Study & Subjects

Antibiotic Use and Resistance Immune responses and vaccinations Vaccine Coverage and Hesitancy

Publication details

Journal / source
Philosophical Transactions of the Royal Society B Biological Sciences
Publisher
The Royal Society
Volume
381
Issue
1944
Publication date
19 February 2026
Language
EN